Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · Real-Time Price · USD
9.74
-0.38 (-3.75%)
At close: Oct 16, 2026, 4:00 PM EDT
10.09
+0.35 (3.59%)
After-hours: Oct 16, 2026, 7:42 PM EDT
Monte Rosa Therapeutics Employees
Monte Rosa Therapeutics had 173 employees as of June 30, 2026. The number of employees increased by 31 or 21.83% compared to the same quarter last year. That makes Monte Rosa Therapeutics the 27,815th largest employer in the world and 3,524th in the United States.
Employees
173
Change
31
Growth
21.83%
Revenue / Employee
$166,052
Profits / Employee
-$931,306
Market Cap
830.95M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 173 | 31 | 21.83% |
| Mar 31, 2026 | 161 | 19 | 13.38% |
| Dec 31, 2025 | 150 | 16 | 11.94% |
| Sep 30, 2025 | 147 | 14 | 10.53% |
| Jun 30, 2025 | 142 | 13 | 10.08% |
| Mar 31, 2025 | 142 | 12 | 9.23% |
| Dec 31, 2024 | 134 | 1 | 0.75% |
| Sep 30, 2024 | 133 | 0 | - |
| Jun 30, 2024 | 129 | -4 | -3.01% |
| Mar 31, 2024 | 130 | -3 | -2.26% |
| Dec 31, 2023 | 133 | 10 | 8.13% |
| Sep 30, 2023 | 133 | 15 | 12.71% |
| Jun 30, 2023 | 133 | 29 | 27.88% |
| Mar 31, 2023 | 133 | 38 | 40.00% |
| Dec 31, 2022 | 123 | 30 | 32.26% |
| Sep 30, 2022 | 118 | 24 | 25.53% |
| Jun 30, 2022 | 104 | 21 | 25.30% |
| Mar 31, 2022 | 95 | 35 | 58.33% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Kura Oncology | 260 |
| Rigel Pharmaceuticals | 174 |
| MoonLake Immunotherapeutics | 130 |
| Odyssey Therapeutics | 100 |
| Alto Neuroscience | 68 |
| Jade Biosciences | 55 |
| Corvus Pharmaceuticals | 37 |
| Arbutus Biopharma | 19 |
GLUE News
- 6 days ago - Monte Rosa Therapeutics assumed with a Buy at UBS - TheFly
- 15 days ago - Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 16 days ago - Monte Rosa Therapeutics Transcript: Study result - Transcripts
- 16 days ago - Monte Rosa Therapeutics Press release: Study result - Filings
- 16 days ago - Monte Rosa Therapeutics Slides: Study result - Filings
- 16 days ago - Monte Rosa announces data from GFORCE-1, plans for Phase 2 program of MRT-8102 - TheFly
- 16 days ago - Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk - GlobeNewsWire
- 16 days ago - Monte Rosa Therapeutics initiated with a Buy at H.C. Wainwright - TheFly